Inflaryl Drug Interactions

DRUG INTERACTIONS: DRUG-DRUG COMBINATIONS: ACENOCOUMAROL: Concomitant diclofenac and oral anticoagulant therapy with acenocoumarol presents an increased risk of serious bleeding, particularly from the gastrointestinal tract.
ALENDRONATE: Because both NSAID and alendronate use has been associated with gastrointestinal irritation, caution should be exercised with concomitant administration.
ANGIOTENSIN CONVERTING ENZYME INHIBITORS: NSAIDs may decrease the antihypertensive and natriuretic effect of ACE inhibitors, particularly in low renin hypertensive patients.
ANISINDIONE: Concomitant diclofenac and oral anticoagulant therapy with anisindione presents an increased risk of serious bleeding, particularly from the gastrointestinal tract.
ASPIRIN: Concomitant administration of aspirin and diclofenac results in aspirin displacing diclofenac from its binding sites. This leads to reduced diclofenac plasma concentrations, peak plasma levels, and area under the concentration-time curve (AUC) values.
BETA-ADRENERGIC BLOCKERS: The concurrent use of nonsteroidal anti-inflammatory drugs (NSAIDs) and beta-adrenergic blockers has been reported to result in increase in blood pressure and interference with blood pressure control.
CALCIUM CHANNEL BLOCKERS: Calcium channel blockers may be associated with an increased risk of gastrointestinal hemorrhage. Caution is advised if NSAIDs and calcium channel blockers are used concomitantly. Monitor for signs and symptoms of gastrointestinal hemorrhage, such as weakness, nausea and blood in the stool. The antihypertensive effects of calcium channel blockers may be antagonized by concomitant administration of NSAIDs.
CHOLESTYRAMINE: It decreases diclofenac absorption in the gastrointestinal tract.
COMFREY: Elevated liver transaminases with or without concomitant hepatic damage.
Comfrey is a known hepatotoxin and should be avoided.
CYCLOSPORINE: The concurrent use of nonsteroidal anti-inflammatory agents (NSAIDs) and cyclosporine has resulted in increases in cyclosporine levels, nephrotoxicity and increased plasma creatinine concentrations.
DICUMAROL: Concomitant diclofenac and oral anticoagulant therapy with dicumarol presents an increased risk of serious bleeding, particularly from the gastrointestinal tract.
DIGOXIN: Increased digoxin serum concentrations have been reported during concurrent therapy with digoxin and diclofenac.
ENALAPRIL/FELODIPINE: Calcium channel blockers may be associated with an increased risk of gastrointestinal hemorrhage.
EPTIFIBATIDE: Concurrent administration of nonsteroidal anti-inflammatory agents and eptifibatide may produce enhanced anticoagulation, leading to an increased risk of internal and superficial hemorrhage.
EUCALYPTUS: Increased risk of hepatotoxicity. Avoid use of eucalyptus while taking drugs with potential for hepatoxicity.
FEVERFEW: Theoretically, concomitant use of feverfew with a nonsteroidal anti-inflammatory agent (NSAID) may predispose the patient to more adverse effects (e.g., gastropathy, increased risk of bleeding and nephropathy).
GERMANDER: Elevated liver transaminases with or without concomitant hepatic damage.
GINKGO: Avoid concomitant use of Ginkgo with any medicine which can inhibit platelet aggregation or coagulation, including non-steroidal anti-inflammatory agents.
GOSSYPOL: Gossypol may cause tissue congestion, mucosal sloughing, mucosal necrosis and intestinal wall hemorrhage.